These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14769135)

  • 21. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
    Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
    Kickingereder P; Hamisch C; Suchorska B; Galldiks N; Visser-Vandewalle V; Goldbrunner R; Kocher M; Treuer H; Voges J; Ruge MI
    J Neurooncol; 2014 Dec; 120(3):615-23. PubMed ID: 25151509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.
    Floyd NS; Woo SY; Teh BS; Prado C; Mai WY; Trask T; Gildenberg PL; Holoye P; Augspurger ME; Carpenter LS; Lu HH; Chiu JK; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):721-6. PubMed ID: 14967426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study.
    Muanza T; Shenouda G; Souhami L; Leblanc R; Mohr G; Corns R; Langleben A
    Can J Neurol Sci; 2000 Nov; 27(4):302-6. PubMed ID: 11097520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).
    Gross MW; Altscher R; Brandtner M; Häusser-Mischlich H; Kiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Strahlenther Onkol; 2001 Dec; 177(12):656-61. PubMed ID: 11789404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy.
    Miwa K; Matsuo M; Ogawa S; Shinoda J; Yokoyama K; Yamada J; Yano H; Iwama T
    Radiat Oncol; 2014 Aug; 9():181. PubMed ID: 25123357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas.
    Grossman SA; Phuphanich S; Lesser G; Rozental J; Grochow LB; Fisher J; Piantadosi S;
    J Clin Oncol; 2001 Jul; 19(13):3260-6. PubMed ID: 11432894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
    Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
    Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
    Li L; Quang TS; Gracely EJ; Kim JH; Emrich JG; Yaeger TE; Jenrette JM; Cohen SC; Black P; Brady LW
    J Neurosurg; 2010 Aug; 113(2):192-8. PubMed ID: 20345222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.